Zituvimet (sitagliptin and metformin hydrochloride) tablets
Approval Date: Nov 2023
Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes
Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Onglyza™ (saxagliptin) tablets
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Tzield® (teplizumab-mzwv) injection
Approval Date: Nov 2022
A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.
Jardiance® (empagliflozin) tablets
Approval Date: Aug 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Synjardy® (empagliflozin and metformin hydrochloride) tablets
Approval Date: Jul 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Mounjaro™ (tirzepatide) injection
Approval Date: May 2022
Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise
Farxiga (dapgliflozin) tablets
Approval Date: Feb 2022
A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.
Rezvoglar (insulin glargine-aglr) injection
Approval Date: Dec 2021
Indicated to improve glycemic control for type 1 and 2 diabetes
Jentadueto® (linagliptin and metformin hydrochloride) tablets
Approval Date: Aug 2021
Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes
